HPQ Silicon and Novacium Sign MOU with GLD Alloys to produce Green Hydrogen with METAGENE(TM)

(TSX-V:HPQ),(OTC US:HPQFF),(Other OTC:HPQFF),(Boerse Frankfurt – Freiverkehr:O08.F), MONTREAL and LYON France, April 10, 2025 (GLOBE NEWSWIRE) — HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company specializing in green engineering processes, along with its French subsidiary NOVACIUM SAS (“Novacium”), is pleased to announce the signing of a Memorandum of […]

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

(NASDAQ:QNRX), Episode Highlights a Truly Remarkable Patient Story Spanning 79 Years Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company's NETHERTON NOW website ASHBURN, Va., April 10, 2025 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a

Dragonfly Energy Wins the 2025 “Battery Technology Company of the Year” CleanTech Breakthrough Award

(NASDAQ:DFLI),(NASDAQ:DFLIW), Selected from thousands of nominations across 14 countries, Dragonfly Energy was named “Battery Technology Company of the Year” for its industry-leading innovations in lithium battery technology. The award highlights the Company's patented dry electrode manufacturing process, which eliminates toxic solvents and energy-intensive drying ovens–reducing environmental impact and enabling scalable, sustainable battery cell production. Dragonfly

Toronto Downtown West BIA Rolls Out Major Sustainability Push for Earth Month and Beyond

Toronto, April 10, 2025 (GLOBE NEWSWIRE) — The Toronto Downtown West BIA (TDWBIA) and its members are celebrating Earth Month with a significant commitment to building a cleaner, greener downtown. From community clean-ups, a new pollinator garden, rooftop beehives and educational events, there are a series of initiatives planned in downtown Toronto that not only

RCP Advisors Closes on RCPDirect V, Exceeding Target Fund Size

(NYSE:PX), DALLAS, April 10, 2025 (GLOBE NEWSWIRE) — P10, Inc. (NYSE: PX), (“P10” or the “Company”), a leading private markets solutions provider, today announced that its strategy, RCP Advisors, a private equity investment firm that provides access to North American small buyout fund managers, closed on its latest co-investment fund, RCPDirect V, LP (“RCP Direct

Paratek Pharmaceuticals to Present New Data on NUZYRA(R) (omadacycline) at ESCMID Global 2025

BOSTON, April 10, 2025 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company developing specialty therapies for community care and public health challenges, today announced that data from several new studies of NUZYRA(R) (omadacycline) will be presented at ESCMID Global 2025, the Congress of the European Society of Clinical Microbiology and Infectious Diseases,

Quantum BioPharma Licensee Celly Nutrition Announces Landmark Partnership with the Asian American Trade Associations Council (AATAC) to Expand Retail Availability of its Alcohol Detox Beverage unbuzzd(TM)

(NASDAQ:QNTM),(CNSX:QNTM.CN),(Boerse Frankfurt – Freiverkehr:0K91), TORONTO, April 10, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company“), today announced its licensee – Celly Nutrition Corporation (“Celly Nutrition“), the company behind unbuzzd(TM) – the beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms – has

WESTERN COPPER AND GOLD PROVIDES INFRASTRUCTURE UPDATE

Western Copper and Gold Corporation (“Western” or the “Company”) (TSX: WRN) (NYSE American: WRN) is pleased to provide an update on several infrastructure initiatives supporting the development of its Casino Copper-Gold Project (“Casino Project”). https://mma.prnewswire.com/media/2661440/Western_Copper_and_Gold_Corporation_WESTERN_COPPER_AND_GOLD_PROV.jpg Sandeep Singh, President and Chief Executive Officer, stated: “Infrastructure is obviously a key piece of the puzzle to bring the

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

— Six-month open-label study showed clinically meaningful improvements in kidney function and disease in patients with Type 2 diabetic nephropathy. — 71% achieved a >30% reduction in UP/Cr, a key indicator of kidney damage. — 71% demonstrated improved or stabilizedeGFR,signalingpreserved kidney function. — 37.5% had increased urinaryVEGF levels,suggesting better blood vessel support in the kidneys.

BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company developing cutting-edge cell therapies for neurodegenerative diseases, today announced the submission of an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA) for NurOwn®, the company's autologous mesenchymal stem cell therapy for amyotrophic lateral sclerosis (ALS). This important milestone sets the

Scroll to Top